ClinicalTrials.gg
RecruitingNCT07145073Updated Jan 30, 2026

Repetitive Transcranial Alternating Current Stimulation (rtACS) for the Treatment of Optic Neuropathies

An interventional study of DC-Stimulator MC and DC-Stimulator MC in Glaucoma, sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by National Taiwan University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
188
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Glaucoma with a site in Taiwan — 3 open to participants now, 3 under way, none of them phase 3. Glaucoma · Taiwan.

Started
2026
the only one that year
No phase
3 of 14
2 open now
Registered
13th of 14
by date
Lead sponsor
4 of 14
National Taiwan University Hospital

Among the 14 studies in Glaucoma with a site in Taiwan, this one is the only one that started in 2026, is one of 3 with no phase, and was the 13th registered.

Glaucoma

1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.

Browse Glaucoma studies →

Open to participants now

3 of the 14 studies in Glaucoma with a site in Taiwan are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Glaucoma with a site in Taiwan, or all of them as a file.
02

Study summary

The goal of this study is to see whether repeated transcranial alternating current stimulation can activate impaired retinal ganglion cells and improve both structural and functional outcomes in patients with glaucoma.

03

Conditions studied

  • Glaucoma

Browse trials for

Keywords

  • Glaucoma
  • electrical stimulation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be at least 18.
  2. Clinical diagnosis of glaucoma, with Humphrey Visual Field 24-2 mean deviation (MD) between -22 dB and -5 dB, and Visual Field Index (VFI) between 10% and 90%. The visual field test at screening must meet the following reliability indices:

    • Fixation losses (FL) ≤ 33%
    • False-negative rate (FNR) ≤ 20%
    • False-positive rate (FPR) ≤ 20% At initial screening, the difference in MD between two consecutive visual field tests must be less than 2 dB.
  3. Best-corrected visual acuity (BCVA) ≥ 0.2 in the worse eye selected for stimulation treatment.
  4. If a participant has two eyes meeting study criteria, one eye will be randomly selected by computer for study participation.
  5. In the opinion of the investigator the participant's eye pressure must be clinically stable.
  6. Participant must has the ability to comply with the requirements of the study and complete the schedule of events.
  7. Participant must understand and sign the . If the participant's vision is impaired to the point where he/she cannot read the informed consent document, the document will be read to the participant in its entirety.
  8. Optical coherence tomography (OCT) imaging shows measurable changes in either peripapillary retinal nerve fiber layer (RNFL) thickness or macular ganglion cell-inner plexiform layer thickness.

Exclusion criteria

Exclusion Criteria:

  1. History of ocular herpes.
  2. Pathological nystagmus.
  3. Retinal disease sufficient to affect vision.
  4. Corneal opacity affecting vision.
  5. Cataract affecting vision.
  6. Uveitis or other intraocular inflammatory disease.
  7. Implanted electronic devices such as a pacemaker.
  8. Rheumatologic or disease.
  9. Brain tumor or intracranial magnetic metallic implants.
  10. History of epilepsy.
  11. Periocular skin lesions.
  12. Anxiety with Geriatric Anxiety Scale score > 12.
  13. History of claustrophobia.
  14. Participation in another clinical trial within the past 3 months involving medication or training that could affect the eyes.
  15. Physical or mental conditions that may increase the risk of participation or interfere with study assessments (e.g., dementia).
  16. Previous ocular electrical stimulation treatment or visual training study within the past 12 months.
  17. Uncontrolled hypertension or diabetes.
  18. Pregnant or breastfeeding.
  19. History of craniotomy, burr hole surgery, head trauma, intracranial tumor, vascular malformation, or intracranial surgery.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
188 participants (estimated)

Study arms

  • Experimental
    Repetitive Transcranial Alternating Current Stimulation treatment

    Participants will receive 10 days of repeated transcranial alternating current stimulation in hospital.

    Device: DC-Stimulator MC

  • Sham comparator
    Sham Repetitive Transcranial Alternating Current Stimulation

    Participants will receive 10 days of repeated transcranial alternating current stimulation treatment (no active stimulation) in hospital.

    Device: DC-Stimulator MC

Interventions

  • DeviceDC-Stimulator MC

    Experimental:Participants will receive 10 days of repeated transcranial alternating current stimulation treatment in hospital.

  • DeviceDC-Stimulator MC

    Sham Comparator:Participants will receive 10 days of repeated transcranial alternating current stimulation treatment (no active stimulation) in hospital.

06

What researchers measure

Primary outcomes

  1. Change in visual field mean deviation (MD) from baseline to post-treatment

    Visual field testing will be performed with the Humphrey field analyzer

    Time frame: From treatment initiation to 26 days after treatment initiation

Secondary outcomes

  1. Change in visual field mean deviation (MD) from baseline to post-treatment

    Visual field testing will be performed with the Humphrey field analyzer

    Time frame: From treatment initiation to 12 days after treatment initiation

  2. Change in visual field mean deviation (MD) from baseline to post-treatment

    Visual field testing will be performed with the Humphrey field analyzer

    Time frame: From treatment initiation to 19 days after treatment initiation

  3. Change in visual field mean deviation (MD) from baseline to post-treatment

    Visual field testing will be performed with the Humphrey field analyzer

    Time frame: From treatment initiation to 166 days after treatment initiation

  4. Change in sensitivity at each of the 52 test points in the 24-2 visual field from baseline to post-treatment

    Time frame: From treatment initiation to 26 days after treatment initiation

  5. Change in targeted mean deviation from baseline to post-treatment

    Time frame: From treatment initiation to 12 days after treatment initiation

  6. Change in targeted mean deviation from baseline to post-treatment

    Time frame: From treatment initiation to 19 days after treatment initiation

  7. Change in targeted mean deviation from baseline to post-treatment

    Time frame: From treatment initiation to 26 days after treatment initiation

  8. Change in targeted mean deviation from baseline to post-treatment

    Time frame: From treatment initiation to 166 days after treatment initiation

  9. Visual function analysis from baseline to post-treatment

    Visual acuity measured by Landolt C Chart.

    Time frame: From treatment initiation to 5 days after treatment initiation

  10. Visual function analysis from baseline to post-treatment

    Contrast sensitivity measured by CSV-1000

    Time frame: From treatment initiation to 5 days after treatment initiation

  11. Visual function analysis from baseline to post-treatment

    Contrast sensitivity measured by Pelli-Robson Contrast Sensitivity Chart

    Time frame: From treatment initiation to 5 days after treatment initiation

  12. Visual function analysis from baseline to post-treatment

    Contrast sensitivity measured by MARS Contrast Sensitivity Chart

    Time frame: From treatment initiation to 5 days after treatment initiation

  13. Visual function analysis from baseline to post-treatment

    Color vision measured by HRR pseudoisochromatic test

    Time frame: From treatment initiation to 5 days after treatment initiation

  14. Visual function analysis from baseline to post-treatment

    Continuous Chinese reading acuity measured by Paragraph Chinese Reading Acuity Test (P-CRAT)

    Time frame: From treatment initiation to 5 days after treatment initiation

  15. Visual function analysis from baseline to post-treatment

    Visual acuity measured by Landolt C Chart

    Time frame: From treatment initiation to 12 days after treatment initiation

  16. Visual function analysis from baseline to post-treatment

    Contrast sensitivity measured by CSV-1000

    Time frame: From treatment initiation to 12 days after treatment initiation

  17. Visual function analysis from baseline to post-treatment

    Contrast sensitivity measured by Pelli-Robson Contrast Sensitivity Chart

    Time frame: From treatment initiation to 12 days after treatment initiation

  18. Visual function analysis from baseline to post-treatment

    Contrast sensitivity measured by MARS Contrast Sensitivity Chart

    Time frame: From treatment initiation to 12 days after treatment initiation

  19. Visual function analysis from baseline to post-treatment

    Color vision measured by HRR pseudoisochromatic test

    Time frame: From treatment initiation to 12 days after treatment initiation

  20. Visual function analysis from baseline to post-treatment

    Continuous Chinese reading acuity measured by Paragraph Chinese Reading Acuity Test (P-CRAT)

    Time frame: From treatment initiation to 12 days after treatment initiation]

  21. Visual function analysis from baseline to post-treatment

    Visual acuity measured by Landolt C Chart

    Time frame: From treatment initiation to 26 days after treatment initiation

  22. Visual function analysis from baseline to post-treatment

    Contrast sensitivity measured by CSV-1000

    Time frame: From treatment initiation to 26 days after treatment initiation

  23. Visual function analysis from baseline to post-treatment

    Contrast sensitivity measured by Pelli-Robson Contrast Sensitivity Chart

    Time frame: From treatment initiation to 26 days after treatment initiation

  24. Visual function analysis from baseline to post-treatment

    Contrast sensitivity measured by MARS Contrast Sensitivity Chart

    Time frame: From treatment initiation to 26 days after treatment initiation

  25. Visual function analysis from baseline to post-treatment

    Color vision measured by HRR pseudoisochromatic test

    Time frame: From treatment initiation to 26 days after treatment initiation

  26. Visual function analysis from baseline to post-treatment

    Continuous Chinese reading acuity measured by Paragraph Chinese Reading Acuity Test (P-CRAT)

    Time frame: From treatment initiation to 26 days after treatment initiation

  27. Visual function analysis from baseline to post-treatment

    Visual acuity measured by Landolt C Chart

    Time frame: From treatment initiation to 166 days after treatment initiation

  28. Visual function analysis from baseline to post-treatment

    Contrast sensitivity measured by CSV-1000

    Time frame: From treatment initiation to 166 days after treatment initiation

  29. Visual function analysis from baseline to post-treatment

    Contrast sensitivity measured by Pelli-Robson Contrast Sensitivity Chart

    Time frame: From treatment initiation to 166 days after treatment initiation

  30. Visual function analysis from baseline to post-treatment

    Contrast sensitivity measured by MARS Contrast Sensitivity Chart

    Time frame: From treatment initiation to 166 days after treatment initiation

  31. Visual function analysis from baseline to post-treatment

    Color vision measured by HRR pseudoisochromatic test

    Time frame: From treatment initiation to 166 days after treatment initiation

  32. Visual function analysis from baseline to post-treatment

    Continuous Chinese reading acuity measured by Paragraph Chinese Reading Acuity Test (P-CRAT)

    Time frame: From treatment initiation to 166 days after treatment initiation

  33. Quality of life analysis from baseline to post-treatment

    Vision-related quality of life assessed using the National Eye Institute 25-Item Visual Function Questionnaire (NEI VFQ-25). Scores are converted to a 0-100 scale, where higher scores indicate better vision-related quality of life.

    Time frame: From treatment initiation to 12 days after treatment initiation

  34. Quality of life analysis from baseline to post-treatment

    Health status assessed using the 36-Item Short Form Health Survey (SF-36). Scores for each domain and the overall score range from 0 to 100, where higher scores indicate better health status.

    Time frame: From treatment initiation to 12 days after treatment initiation

  35. Quality of life analysis from baseline to post-treatment

    Mobility in daily life assessed using the Mobility questionnaire. This questionnaire focuses on difficulties related to mobility and driving. Scores are reported on a 0-172 scale, where higher scores indicate greater difficulty with mobility and driving in daily life.

    Time frame: From treatment initiation to 12 days after treatment initiation

  36. Quality of life analysis from baseline to post-treatment

    Vision-related quality of life assessed using the National Eye Institute 25-Item Visual Function Questionnaire (NEI VFQ-25). Scores are converted to a 0-100 scale, where higher scores indicate better vision-related quality of life.

    Time frame: From treatment initiation to 166 days after treatment initiation

  37. Quality of life analysis from baseline to post-treatment

    Health status assessed using the 36-Item Short Form Health Survey (SF-36). Scores for each domain and the overall score range from 0 to 100, where higher scores indicate better health status.

    Time frame: From treatment initiation to 166 days after treatment initiation

  38. Quality of life analysis from baseline to post-treatment

    Mobility in daily life assessed using the Mobility questionnaire. This questionnaire focuses on difficulties related to mobility and driving. Scores are reported on a 0-172 scale, where higher scores indicate greater difficulty with mobility and driving in daily life.

    Time frame: From treatment initiation to 166 days after treatment initiation

  39. Optical coherence tomography (OCT) analysis from baseline to post-treatment

    Peripapillary retinal nerve fiber layer (RNFL) thickness (μm)

    Time frame: From treatment initiation to 12 days after treatment initiation

  40. Optical coherence tomography (OCT) analysis from baseline to post-treatment

    Macular ganglion cell-inner plexiform layer thickness (μm)

    Time frame: From treatment initiation to 12 days after treatment initiation

  41. Optical coherence tomography (OCT) analysis from baseline to post-treatment

    Optic nerve head cup-to-disc ratio (%)

    Time frame: From treatment initiation to 12 days after treatment initiation

  42. Optical coherence tomography (OCT) analysis from baseline to post-treatment

    Peripapillary retinal nerve fiber layer (RNFL) thickness (μm)

    Time frame: From treatment initiation to 26 days after treatment initiation

  43. Optical coherence tomography (OCT) analysis from baseline to post-treatment

    Macular ganglion cell-inner plexiform layer thickness (μm)

    Time frame: From treatment initiation to 26 days after treatment initiation

  44. Optical coherence tomography (OCT) analysis from baseline to post-treatment

    Optic nerve head cup-to-disc ratio (%)

    Time frame: From treatment initiation to 26 days after treatment initiation

  45. Optical coherence tomography (OCT) analysis from baseline to post-treatment

    Peripapillary retinal nerve fiber layer (RNFL) thickness (μm)

    Time frame: From treatment initiation to 166 days after treatment initiation

  46. Optical coherence tomography (OCT) analysis from baseline to post-treatment

    Macular ganglion cell-inner plexiform layer thickness (μm)

    Time frame: From treatment initiation to 166 days after treatment initiation

  47. Optical coherence tomography (OCT) analysis from baseline to post-treatment

    Optic nerve head cup-to-disc ratio (%)

    Time frame: From treatment initiation to 166 days after treatment initiation

  48. Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment

    Peripapillary vessel density

    Time frame: From treatment initiation to 12 days after treatment initiation

  49. Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment

    capillary density

    Time frame: From treatment initiation to 12 days after treatment initiation

  50. Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment

    Superficial density

    Time frame: From treatment initiation to 12 days after treatment initiation

  51. Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment

    deep density

    Time frame: From treatment initiation to 12 days after treatment initiation

  52. Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment

    foveal vessel density

    Time frame: From treatment initiation to 12 days after treatment initiation

  53. Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment

    parafoveal vessel density

    Time frame: From treatment initiation to 12 days after treatment initiation

  54. Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment

    Foveal avascular zone (FAZ)

    Time frame: From treatment initiation to 12 days after treatment initiation

  55. Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment

    Peripapillary vessel density

    Time frame: From treatment initiation to 26 days after treatment initiation

  56. Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment

    capillary density

    Time frame: From treatment initiation to 26 days after treatment initiation

  57. Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment

    Superficial density

    Time frame: From treatment initiation to 26 days after treatment initiation

  58. Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment

    deep density

    Time frame: From treatment initiation to 26 days after treatment initiation

  59. Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment

    foveal vessel density

    Time frame: From treatment initiation to 26 days after treatment initiation

  60. Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment

    parafoveal vessel density

    Time frame: From treatment initiation to 26 days after treatment initiation

  61. Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment

    Foveal avascular zone (FAZ)

    Time frame: From treatment initiation to 26 days after treatment initiation

  62. Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment

    Peripapillary vessel density

    Time frame: From treatment initiation to 166 days after treatment initiation

  63. Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment

    capillary density

    Time frame: From treatment initiation to 166 days after treatment initiation

  64. Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment

    Superficial density

    Time frame: From treatment initiation to 166 days after treatment initiation

  65. Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment

    deep density

    Time frame: From treatment initiation to 166 days after treatment initiation

  66. Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment

    foveal vessel density

    Time frame: From treatment initiation to 166 days after treatment initiation

  67. Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment

    parafoveal vessel density

    Time frame: From treatment initiation to 166 days after treatment initiation

  68. Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment

    Foveal avascular zone (FAZ)

    Time frame: From treatment initiation to 166 days after treatment initiation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2027, 23 months after the start.

Of 230 non-industry interventional studies with no phase under Glaucoma, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 23 months is below that.

Counting every sponsor, half of 288 studies reached it within 30 months; a quarter within 12 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2025
First posted
Aug 28, 2025
StartActual
Jan 26, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07145073
Responsible party
Sponsor
First posted
Aug 28, 2025
Start date
Jan 26, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jan 30, 2026

Study contacts

Chien-Chia Su
Contact
chienchiasu@ntu.edu.tw
+886 972653340
Yu-Cen Ma
Contact
s431075656@gmail.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion